Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of ROSIglitazone on inflammatory markers and adipokines in diabetic patients using an angiotensin receptor blocker (TELmisartan) - the ROSITEL study.

Trial Profile

Effects of ROSIglitazone on inflammatory markers and adipokines in diabetic patients using an angiotensin receptor blocker (TELmisartan) - the ROSITEL study.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Metformin; Rosiglitazone; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms ROSITEL
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Nov 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 24 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top